secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2026-01-22T23:59:59+00:00
Accession:  0001140361-26-001958
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech receives U.S. patent allowance for PDS0101 with 20-year market protection
--------------------------------------------------------------------------------

- U.S. Patent Office issued Notice of Allowance for PDS0101 (Application 16/210,750) covering cationic lipid compositions.
- New patent plus biologics exclusivity expected to provide ~20 years of market protection for PDS0101.
- PDS0101 is in Phase 3 VERSATILE-003 trial for HPV16-positive head and neck cancers.
- Company submitted FDA protocol amendment proposing PFS as primary endpoint for potential accelerated approval.
- IP estate includes granted patents in U.S., Europe, Japan, China, Australia, Canada, Israel, Mexico, and Hong Kong.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036126001958/0001140361-26-001958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036126001958/ef20063617_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-001958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer